Logo image of IMMP

IMMUTEP LTD-SP ADR (IMMP) Stock Fundamental Analysis

USA - NASDAQ:IMMP - US45257L1089 - ADR

1.61 USD
-0.08 (-4.73%)
Last: 9/19/2025, 8:19:18 PM
1.61 USD
0 (0%)
After Hours: 9/19/2025, 8:19:18 PM
Fundamental Rating

3

Taking everything into account, IMMP scores 3 out of 10 in our fundamental rating. IMMP was compared to 540 industry peers in the Biotechnology industry. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMMP had negative earnings in the past year.
IMMP had a negative operating cash flow in the past year.
IMMP had negative earnings in each of the past 5 years.
IMMP had a negative operating cash flow in each of the past 5 years.
IMMP Yearly Net Income VS EBIT VS OCF VS FCFIMMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

The Return On Assets of IMMP (-24.06%) is better than 74.07% of its industry peers.
Looking at the Return On Equity, with a value of -25.43%, IMMP belongs to the top of the industry, outperforming 80.37% of the companies in the same industry.
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROIC N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMMP Yearly ROA, ROE, ROICIMMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMP Yearly Profit, Operating, Gross MarginsIMMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

More info and screens

6

2. Health

2.1 Basic Checks

IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMMP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IMMP has been increased compared to 5 years ago.
Compared to 1 year ago, IMMP has a worse debt to assets ratio.
IMMP Yearly Shares OutstandingIMMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
IMMP Yearly Total Debt VS Total AssetsIMMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 19.68 indicates that IMMP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 19.68, IMMP belongs to the best of the industry, outperforming 91.85% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that IMMP is not too dependend on debt financing.
IMMP has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.68
ROIC/WACCN/A
WACC9.71%
IMMP Yearly LT Debt VS Equity VS FCFIMMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.86, IMMP belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
A Quick Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
IMMP has a better Quick ratio (18.86) than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 18.86
Quick Ratio 18.86
IMMP Yearly Current Assets VS Current LiabilitesIMMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IMMP have decreased strongly by -14.43% in the last year.
Looking at the last year, IMMP shows a very negative growth in Revenue. The Revenue has decreased by -49.75% in the last year.
The Revenue for IMMP have been decreasing by -66.35% on average. This is quite bad
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%

3.2 Future

The Earnings Per Share is expected to grow by 75.20% on average over the next years. This is a very strong growth
IMMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.43% yearly.
EPS Next Y-23.66%
EPS Next 2Y13.11%
EPS Next 3Y47.85%
EPS Next 5Y75.2%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y250.6%
Revenue Next 5Y123.43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMMP Yearly Revenue VS EstimatesIMMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
IMMP Yearly EPS VS EstimatesIMMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IMMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMP Price Earnings VS Forward Price EarningsIMMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMP Per share dataIMMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

IMMP's earnings are expected to grow with 47.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.11%
EPS Next 3Y47.85%

More info and screens

0

5. Dividend

5.1 Amount

IMMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUTEP LTD-SP ADR

NASDAQ:IMMP (9/19/2025, 8:19:18 PM)

After market: 1.61 0 (0%)

1.61

-0.08 (-4.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2025-08-29/bmo
Earnings (Next)02-24 2026-02-24
Inst Owners42.51%
Inst Owner Change0.37%
Ins Owners2.14%
Ins Owner ChangeN/A
Market Cap234.19M
Analysts82.22
Price Target2.31 (43.48%)
Short Float %3.05%
Short Ratio54.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.21%
PT rev (3m)-7.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-13.49%
EPS NY rev (3m)-13.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)25.07%
Revenue NY rev (3m)25.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6549.22
P/FCF N/A
P/OCF N/A
P/B 2.04
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.79
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1556.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.86
Quick Ratio 18.86
Altman-Z 19.68
F-Score2
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
EPS Next Y-23.66%
EPS Next 2Y13.11%
EPS Next 3Y47.85%
EPS Next 5Y75.2%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y250.6%
Revenue Next 5Y123.43%
EBIT growth 1Y-12.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.66%
EBIT Next 3Y43.27%
EBIT Next 5Y27.17%
FCF growth 1Y-10.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A